港股異動丨固生堂(2273.HK)上市首日大漲10.69% 每手浮盈310港元
格隆匯12月10日丨固生堂(2273.HK)上市首日大漲10.69%,報32.1港元,總市值74億港元。不計手續費,每手浮盈310港元。固生堂是一家中醫醫療健康服務提供商,IPO前,旗下擁有42家中醫診所。根據招股書,在中國採用新中醫醫療模式的民營中醫醫療機構中,固生堂醫療健康解決方案收入、線下醫療機構數目與中醫師數目皆排名第一。作為第一家登陸港交所的中醫連鎖品牌,固生堂獲得眾多知名投資機構認可,基石投資者包括睿遠基金、博裕資本、鋭智資本、瑞銀新加坡四家,合共認購總額為4200萬美元或約3.56億港元的有關數目的發售股份,約佔發售股份的約42%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.